Practice For Pharmacodynamics Exam 3

A) vasodilation

B) sterile inflammation

C) cholinergic reflux

D) vasoconstriction of anastomoses

A) Sumatriptan

B) Eletriptan

C) Naratriptan

D) Frovatriptan

True

False

A) Use of ergotamine, DHE, or other ergot preparations within the prior 24 hours

B) Use of monoamine oxidase inhibitor (MAOI) within the past 2weeks due to increased risk of "serotonin syndrome"

C) Use of Acetylcholinesterase inhibitors

D) uncontrolled hypertension

A) decreased serotonin release

B) increased likelihood of emesis and nausea

C) Activation of 5HT3 receptors

D) b,c

E) a,b

A) Yes, metoclopramide is an alternative anti-emesis drug

B) No, this drug may aggravate the patients Parkonsonism

C) No, this drug is indicated for nausea but contraindicated if the patient is vomiting

D) No, this drug will not have an effect in Parkinson’s patients due their lack of substancia nigra which is involved in metoclopramides mechanism of action

A) No, there is no contraindication listed for these two medications

B) Contraindication in use of Lotronex is presence of hypertension

C) Contraindication is increased risk of constipation in addition to the risk already posed by alosetron

D) b and c

A) Cyproheptadine has a side effect of increased sweating which may be resulting in dehydration

B) Cyproheptadine is antagonizing serotonin receptors in the gut

C) Cyproheptadine decreases thirst resulting is reduced water intake

D) Blockade of central muscarinic receptors

A) Triptan’s work quicker

B) Triptan’s absorb better

C) Triptan’s do not have to be given with metoclopramide in certain patients to enhance gastric emptying and reduce nausea while using the drug

D) All of the above

A) Increases release of NE and DA which will cause vasodilation

B) Inhibits endothelial release of nitric oxide

C) inhibits release of histamine from mast cells

D) a and b

E) b and c

A) painful extremities

B) peripheral ischemia

C) nausea and vomiting

D) continuous paresthesias

True

False

A) Ergot alkaloids

B) Antidepressants

C) NSAIDs

D) Serotonin agonists

E) Acetaminophen

A) Beta-blockers

B) Beta-blockers with intrinsic sympathomimetic activity

C) Anticonvulsants

D) Calcium channel blockers

A) 5-HT1B and 5-HT1D

B) Dopamine

C) Norepinephrine

D) Cholinergic

True

False

A) Trigeminovascular

B) Perivascular

C) Extravascular

D) Tuberofundibular

True

False

A) cyproheptadine

B) mitotane

C) ketoconazole

D) aminoglutethimide

A) adrenocorticotropic hormone

B) corticotropin-releasing hormone

C) melanocyte-stimulating hormone

D) renin

A) zona glomerulosa

B) zona fasciculate

C) zona reticularis

D) medulla

A) adrenal carcinoma

B) primary pigmented nodular adrenal disease

C) adrenal adenoma

D) pituitary adenoma

A) Spironolactone

B) Mifepristone

C) Angiotensin receptor blockers

D) Partial adrenalectomy

A) 5 tablets today OTD

C) 1 tablet every day for 5 days

B) 5 tablets today UD, 4 tablets on 2nd day UD, 4 tablets on 3rd day UD, 3 tablets on 4th day UD, 2 tablets on 5th day as directed, and 1 tablet on the 6th day UD (UD = as directed)

D) None of the above is appropriate

A) Weight gain and insomnia often occur when starting treatment

B) Chronic use can lead to osteoporosis and glaucoma for which they must be monitored.

C) Patients should wear medical identification stating they are on chronic steroid therapy.

D) Patients may need to decrease dose during times of increased stress.